Rapid detection of SARS-CoV-2 B.1.1.529 (Omicron BA.1) variant by SYBR Green□based RT□qPCR

Fadi Abdel-Sater¹, Rawan Makki¹, Alia Khalil¹, Nader Hussein¹, Nada Borghol¹, Ziad Abi
Khattar¹, Aline Hamade¹, Nathalie Khreich¹, Mahoumd El Homsi¹, Hussein Kanaan¹, Line
Raad¹, Najwa Skafi¹, Fatima Al-Nemer¹, Zeinab Ghandour¹, Nabil El-Zein¹, Mohamad AbouHamdan¹, Haidar Akl¹, Eva Hamade¹, Bassam Badran¹^{\$}, Kassem Hamze^{1, \$}

¹Laboratory of Molecular Biology and Cancer Immunology (Covid 19 Unit), Faculty of science
I, Lebanese University, Hadath, Beirut, LB 1003.

9

10 **Corresponding author**:

Kassem Hamze: Laboratory of Molecular Biology and Cancer Immunology (Covid 19 Unit),
Faculty of Science I, Lebanese University, Hadath, Beirut, LB 1003; e-mail:
kassem.hamze@ul.edu.lb, phone number: 0096170258296.

Bassam Badran: Laboratory of Molecular Biology and Cancer Immunology (Covid 19 Unit),
Faculty of Science I, Lebanese University, Hadath, Beirut, LB 1003; e-mail:
bassam.badran@ul.edu.lb, phone number: 00961675642.

17

18 ^{\$} Co-corresponding authors

20 Abstract

21 The COVID-19 pandemic is unceasingly spreading across the globe, and recently a highly transmissible Omicron SARS-CoV-2 variant (B.1.1.529) has been discovered in South Africa 22 23 and Botswana. Rapid identification of this variant is essential for pandemic assessment and containment. However, variant identification is mainly being performed using expensive and 24 time-consuming genomic sequencing. In this study we propose an alternative RT-qPCR 25 approach for the detection of the Omicron BA.1 variant using a low-cost and rapid SYBR Green 26 method. We have designed specific primers to confirm the deletion mutations in the spike (S 27 Δ 143-145) and the nucleocapsid (N Δ 31-33) which are characteristics of this variant. For the 28 evaluation, we used 120 clinical samples from patients with PCR-confirmed SARS-CoV-2 29 infections, and displaying an S-gene target failure (SGTF) when using TaqPath COVID-19 kit 30 (Thermo Fisher Scientific, Waltham, USA) that included the ORF1ab, S, and N gene targets. Our 31 32 results showed that all the 120 samples harbored S Δ 143-145 and N Δ 31-33, which was further 33 confirmed by Whole genome sequencing (WGS) of 10 samples thereby validating our SYBR 34 Green-based protocol. This protocol can be easily implemented to rapidly confirm the diagnosis of the Omicron BA.1 variant in COVID-19 patients and prevent its spread among populations, 35 especially in countries with high prevalence of SGTF profile. 36

37

Keywords: Omicron variant, COVID-19 pandemic, SARS CoV-2, SYBR Green-based RT qPCR

- 40
- 41

42 **1. Introduction**

43 The World Health Organization has declared the COVID-19 outbreak in China a global 44 pandemic on March 2020. Since then, the causative agent, severe acute respiratory syndrome 45 coronavirus 2 (SARS-CoV-2), has been extensively investigated, with more than 8,313,147 million genomic sequences obtained and made freely available on the GISAID database on 46 47 February 16, 2022. As the SARS-CoV-2 spreads over the globe, a natural process of random mutations and evolution continues (Habas et al., 2020, Li et al., 2020). In some circumstances, a 48 mutation provides an evolutionary advantage for the virus, resulting in the emergence of a novel 49 50 viral lineage that outnumbers previous forms. Many SARS-CoV-2 variants have emerged in 51 various regions of the world, and five of them, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), 52 Delta (B.1.617.2), and, most recently, Omicron (BA.1), have been designated as variants of 53 concern (VOC) due to their increased transmissibility, virulence, and/or ability to evade 54 immunity (Davies et al., 2021, Faria et al., 2021, Tagally et al., 2021, Otto et al., 2021, Cele et al., 2022, Planas et al., 2022). Because of its unusual mutational profile and rapid increase in 55 56 prevalence, the Omicron variant, first found in South Africa and Botswana in November 2021, acquired its VOC classification within days, displacing pre-existing lineages in that country. 57 58 Omicron has since surpassed pre-existing variants in Europe, the United States, and a number of 59 other countries, causing a new worldwide outbreak. Omicron (BA.1) displays more than 55 mutations in its genome, with 33 of them occurring only in the spike(S) protein among which 60 61 three deletions ($\Delta 69-70$, $\Delta 143-145$, $\Delta 211$) and one insertion (ins214EPE). Also, the nucleocapsid (N) protein contains four mutations including one deletion $\Delta 31-33$, and three substitutions 62 (P13L, R203K, G204R) (Planas et al., 2022, Callaway, 2021). 63

64 The rapid spreading of Omicron across the globe urge the need to establish a rapid and low-cost diagnostic tool that could quickly and efficiently detect and track it in order to initiate response 65 and proper policy for pandemic containment. Until now, sequencing is considered as the gold-66 67 standard method for identifying SARS-CoV-2 variants. This method is accurate but timeconsuming and expensive. Alternatively, rapid and low-cost RT-qPCR detection methods were 68 proposed recently including the use of a range of primers specific for mutations common to 69 70 VOCs (Abdel Sater et al., 2021, Corman et al., 2020, Borsova et al., 2021, Granato et al., 2021, Zelyas et al., 2021, Vega-Magana et al., 2021, Bedotto et al., 2021), or utilizing commercial kits 71 72 such as TaqPath COVID-19 diagnostic tests (Thermo Fisher Scientific, Waltham, USA) that 73 included the ORF1ab, S, and N gene targets. Some of the SARS-CoV-2 VOCs, Alpha (B.1.1.7) and Omicron (BA.1), generate dropout of the S-gene result in TaqPath kit, with positive results 74 for the other targets (ORF1ab and N genes). This feature has been used as an indicator or 75 screening method to identify these particular variants. The failure of the S-gene target is caused 76 77 by a deletion mutation $\Delta 69-70$ in the respective gene and is called the S-gene target failure (SGTF). Following the use of TaqPath kit, confirmation of the Omicron variant can be 78 performed by specific RT-PCR assays targeting mutations that are characteristic to this variant 79 80 (S \triangle 143-145 and N \triangle 31-33) with mutation-matched primers or probes, and identification through amplification and melting curve analyses (Dachert et al., 2021). However, at least a 81 82 subset of samples should be further characterized by sequencing to increase the confidence and 83 reliability of the obtained results [15].

In 16 Febuary 2022, 1,200,309 Omicron sequences have been shared worldwide through the GISAID, among them 1,129,379 sequences belong to the BA.1 sub-variant (94,09%), and all harboring the S Δ 143-145 and N Δ 31-33 mutations. Consequently, we report here a low-cost

SYBR Green-based qPCR protocol for the rapid and specific detection of these two deletion mutations. We propose primer sets, specific to S Δ 143-145, and N Δ 31-33, that could be applied as a second step to confirm the diagnosis when the number and proportion of SGTF are steadily increasing when using the Applied Biosystems TaqPath RT-PCR COVID-19 kit (Thermo Fisher Scientific, Waltham, USA).

92

2. MATERIALS AND METHODS

93 **2.1. Clinical specimens**

94 220 clinical nasopharyngeal samples were collected and selected for this study from 03 to 22 95 December. All these samples were previously tested for the presence of SARS-CoV-2 at the 96 Laboratory of Molecular Biology and Cancer Immunology of the Lebanese University, using the 97 Applied BiosystemsTM TaqPathTM COVID-19 assay which targeted the RdRp, N and S genes. 98 120 of these clinical samples were positive for SARS-CoV-2 by TaqPath kit with SGTF profile 99 and 100 clinical samples were negative for SARS-CoV-2. Written informed consent was 97 provided by all participants.

101

102 RNA was extracted from 200 μ L of VTM from the clinical samples on Kingfisher flex 103 purification system (Thermo Fisher) using MagMAXTM Viral/Pathogen Nucleic Acid Isolation 104 Kit (Thermo fisher). Reactions were performed in a 20 μ L final volume reaction containing 5 μ L 105 of extracted RNA. RT-qPCR was performed using QuantStudio 5 real-time PCR detection 106 system (Thermo fisher) and TaqPath 2019-nCoV real-time PCR kit (Thermo fisher), which 107 targeted the RdRp, N and S genes of SARS-CoV-2.

2.2. RNA extraction and SARS-CoV-2 qRT-PCR

108 For the validation of Omicron variant in SARS-CoV-2 positive samples, total RNA was 109 retrotranscribed into cDNA using iScript cDNA synthesis kit (BioRad), following the

manufacturer's recommended procedures. Quantitative RT-PCR was carried out using iTaq
universal SYBR Green super mix (Bio Rad). Real-time PCR was performed using Bio Rad
CFX96 Real Time PCR Machine. The thermal cycling conditions used were as follows: 94 °C
for 2 min, followed by 40 cycles of amplification at 94°C for 10 seconds, and 60°C for 1 minute.
The reaction was completed by determining the dissociation curve of all amplicons.

115 **2.3. Primer design**

Primers were designed based on the full sequence of the Wuhan SARS-CoV-2 genome sequence from NCBI nucleotide database (NC_045512) and the full sequence of B.1.1.529 (BA.1) variant (EPI_ISL_6640917) from GISAID EpiCoV database (Fig 1). Bioinformatics tools were used to design and verify the SARS-CoV-2 specific primers. We validated our PCR primers *in-silico* with the PCR Primer-Blast tool which allows to investigate the amplification targets of primers to thereby ensuring adequate specificity. The primer sets used in this study were synthesized and delivered by Macrogen (Republic of Korea) (Table 1).

123

2.4. Genome sequencing and lineage analysis

124 Ten samples displaying the Omicron variant profile by RT-PCR analysis were selected for genome sequencing. Samples were sequenced using the Nanopore MinION methodology and 125 consensus sequences were generated using the bioinformatics SOP (https://artic.network/ncov-126 127 2019/ncov2019-bioinformatics-sop.html) in Nanopolish mode. Sequences obtained were deposited in GISAID database under the accession numbers EPI_ISL_7651286 to 128 129 EPI_ISL_7651289, EPI_ISL_11327269, EPI_ISL_11327268, EPI_ISL_11327263, 130 EPI_ISL_11327262, EPI_ISL_11327252 and EPI_ISL_11327251, were collected from 03 to 06 December 2021. 131

- 132
- 133 **3. Results**

ь

134 Surveillance data, in the Laboratory of Molecular Biology and Cancer Immunology at the 135 Lebanese University, revealed, the re-emergence of SGTF profile with a traveler coming from Abidjan on December 3, 2021. This sample was identified as Omicron BA.1 by whole genome 136 137 sequencing. Since then, the number and the proportion of samples with SGTF profile were steadily increasing and have reached, as of January 10, approximately 95% of positive cases 138 among passengers coming to Lebanon. This dramatic increase in SGTF percentage, suspected as 139 140 Omicron BA.1 variant, urge the need for a rapid and accurate diagnostic tool to detect and track this variant. In this study, we developed a SYBR Green-based RT-qPCR assay for the detection 141 142 of Omicron BA.1 variant. Our design was based on the differences in gene sequence from the 143 original SARS-CoV-2 sequence (Fig. 1, Table 1).

The Omicron BA.1 contains several specific mutations that could potentially serve as a good tool 144 145 for timely detection. These include a nine nucleotide deletions in the S gene Δ 143-145, and other 146 nine nucleotide deletions in the N gene Δ 31-33. Accordingly, two groups of primers were 147 designated. The first group detect the two mutations (spike del 143-145, and N del 31-33) was 148 designed to detect these two mutations whereas, the second group (spike WT 143-145 and N WT 149 31-33) was designed to detect variants not harboring these deletions. A last primer pair (spike control) was designed from within the S gene in a region common to all variants including 150 151 Omicron, and was used as a control for cDNA synthesis and to ensure RNA integrity.

152 Calibration curve and limit of detection

In order to validate their accuracy and efficacy, the newly designed primer set underwent optimization by testing them on a serial 10-fold dilution of cDNA template as follows: 50, 5, 0.5, 0.05, 0.005, 0.0005 and 0.00005 ng/μl. All diluted samples were tested in triplicates by the gold

standard TaqMan RT- qPCR (TaqPath kit) and by our SYBR Green- based RT-qPCR protocol(Table 2).

158 A calibration curve was generated for all the primer sets listed in table 2, using the serial dilution 159 results. Linear regression performed for these primers sets demonstrated strong correlation (Fig. 2). A limit of detection (LOD) was determined for each primer set and identified as 0.0005 160 ng/µL for the two sets (Table 2, Fig. 2), or with maximal Ct of 34.05 or 35.5 obtained by 161 TaqMan and SYBR Green RT-PCR respectively, resulting in a highly sensitive detection. 162 Moreover, the specificity of our primers was investigated by three different ways: i) using 100 163 clinical negative samples for SARS-CoV-2 by TaqPath kit; they did not manifest a signal when 164 tested with such negative controls. ii) using in silico prediction analyses as described in the 165 Material and Methods section, and iii) by WGS of 10 samples. 166

To avoid any false-positive signals resulting from nonspecific products or primer-dimers, a melting curve analysis was included at the end of each PCR assay to determine the specificity and efficiency of each RT-qPCR reaction. Accuracy of our primers to amplify single amplicon is represented as single peak in melting curves (Fig. 3).

171 Clinical evaluation of Spike del 143-145 and N del 31-33 primer sets

After full optimization of the newly designed primer sets and the verification of their sensitivity and specificity in our qPCR assay, they were employed on 120 clinical samples positive for SARS-CoV-2, collected between 03 and 22 December 2021, and which have displayed a Ct < 30 with an SGTF profile, as revealed by the TaqPath kit. Our results showed that the spike controlgene amplicons were detected in all samples, providing evidence of cDNA synthesis and sample integrity preservation (Online Resource 1). Importantly, the S del 143-145-gene amplicons were detected in all the 120 samples, indicating the presence of the S Δ 143-145 deletion and obviously

179	the absence of the amino acids 143, 144 and 145 in the spike protein of these samples (Online
180	Resource 1). Similar results were obtained for the N del 31-33-gene, amplicons were also
181	detected in all the 120 samples indicating the presence of the N Δ 31-33 deletion and the absence
182	of the amino acids 31, 32 and 33 in the nucleocapsid protein of these samples. The use of S WT
183	143-145 and N WT 31-33 primers did not result in amplified product in any of the samples,
184	thereby indicating that the S Δ 143-145 and N Δ 31-33 deletions are located within the genomic
185	region targeted by these two primer sets.
186	The amplification results obtained with spike del 143-145 and N del 31-33 primers were fully
187	concordant with S WT 143-145 and N WT 31-33 primers, 100% of the SGTF samples harboring
188	both S Δ 143-145 and the N Δ 31-33 deletions (Online Resource 1).
189	Furthermore, ten of the S-negative samples were sequenced by WGS at the Microbial
190	Pathogenomics Laboratory of the Lebanese American University (LAU) and sequences obtained
191	were deposited in GISAID database under the accession number EPI_ISL_7651286 to
192	EPI_ISL_7651289, EPI_ISL_11327269, EPI_ISL_11327268, EPI_ISL_11327263,
193	EPI_ISL_11327262, EPI_ISL_11327252 and EPI_ISL_11327251. Sequence data analysis
194	revealed that the ten samples belonged to the Omicron variant, while analyses of more sequences
195	are in progress.

196

197 **4.** Conclusion

198 The protocol we described herein is faster, simpler and more cost-effective than genome 199 sequencing-based method. The uniqueness of the targeted mutations (S Δ 143-145 and N Δ 31-33) 200 renders this protocol highly accurate and amply adequate to the early identification of the 201 suspected samples as Omicron BA.1 when genome sequencing is unavailable. In conclusion, this

202	mutation-specific PCR assay would allow any laboratory having the ability to conduct PCR
203	assays to rapidly and reliably screen for Omicron BA.1 among all SARS-CoV-2 positive samples
204	with SGTF profile, in order to enhance surveillance capacity to identify cases and support
205	decision making for interrupting transmission.
206	
207	Author contributions
208	FAS and KH Conceived and designed the experiments. RM, AK, NH, NB, ZAK, AH, NK, HK, LR,
209	NS, FAN, ZG, NEZ and EH Performed the molecular biology assays. KH and FAS Analyzed and
210	interpreted the data. The first draft of the manuscript was written by KH, FAS and NH. ZAK,
211	AH and NK commented on the first draft of the manuscript. All authors read and approved the
212	final manuscript.
213	Funding

This work was supported by Grants from the Lebanese University.

215

216 Availability of data and materials

We declared that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality.

220 Ethics approval and consent to participate

All presented cases or their legal guardian provided consent to data collection and use according

to institutional guidelines.

223 **Consent for publication**

- All presented cases or their legal guardian provided consent to publish according to institutional
- 225 guidelines.

226 Competing interests

- 227 The authors declare no competing interests.
- 228

229 **References**

- 230 1. Habas, K., Nganwuchu, C., Shahzad, F., Gopalan, R., Haque, M., Rahman, S.,
- 231 Majumder, A.A, Nasim, T., 2020. Resolution of coronavirus disease 2019 (COVID-
- 232 19). Expert review of anti-infective therapy, 18(12), 1201-1211,
 233 https://doi.org/10.1080/14787210.2020.1797487.
- Li, X., Wang, W., Zhao, X., Zai, J., Zhao, Q., Li, Y., Chaillon, A., 2020. Transmission
 dynamics and evolutionary history of 2019-nCoV. J Med Virol. 92(5):501-511. doi:
 10.1002/jmv.25701.
- Davies, N.G., Jarvis, C.I., CMMID COVID-19 Working Group, Edmunds, W.J., Jewell,
 N.P., Diaz-Ordaz, K., Keogh, R.H., 2021. Increased mortality in community-tested cases
 of SARS-CoV-2 lineage B.1.1.7. Nature. 593 (7858):270-274. doi: 10.1038/s41586-021-
- 240 03426-1.
- 4. Faria, N.R., Mellan, T.A., Whittaker, C., Claro, I.M., Candido, D.D.S., Mishra, S., et al.,
- 242 2021. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.
 243 Science. 372(6544):815- 21. https://doi.org/10.1126/science.abh2644
- 5. Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., et
- al., 2021. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature.
- 246 592:438-443. https://doi.org/10.1038/s41586-021-03402-9

247	6.	Otto, S.P., Day, T., Arino, J., Colijn, C., Dushoff, J., Li, M., Mechai, S., Van Domselaar,
248		G., Wu, J., Earn, D.J.D., Ogden, N.H., 2021. The origins and potential future of SARS-
249		CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr Biol. 31(14):
250		R918-R929. doi: 10.1016/j.cub.2021.06.049.
251	7.	Cele, S., Jackson, L., Khoury, D.S., Khan, K., Moyo-Gwete, T., Tegally, H., et al., 2022.
252		Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature.
253		602, 654–656. doi: 10.1038/s41586-021-04387-1.
254	8.	Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J.,
255		et al., 2022. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
256		Nature. 602, 671–675. doi: 10.1038/s41586-021-04389-z.
257	9.	Callaway, E., Heavily mutated Omicron variant puts scientists on alert. Nature. 2021. doi:
258		10.1038/d41586-021-03552-w.
259	10	Kannan, S., Shaik Syed Ali, P., Sheeza, A., 2021. Omicron (B.1.1.529) - variant of
260		concern - molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol
261		Sci. 25(24):8019-8022. doi: 10.26355/eurrev_202112_27653.
262	11	Abdel Sater, F., Younes, M., Nassar, H., Nguewa, P., Hamze, K., A rapid and low-cost
263		protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-
264		based RT-qPCR. Mol Biol Rep. 2021; 48(11):7243-7249. doi: 10.1007/s11033-021-
265		06717-у.
266	12	. Corman, V.M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D.K., et al.,
267		2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro
268		Surveill. 25(14):20200409c. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.

269	13. Boršová, K., Paul, E.D., Kováčová, V., Radvánszka, M., Hajdu, R., Čabanová, V.
270	Sláviková, M., Ličková, M., Lukáčiková, Ľ., Belák, A., Roussier, L., Kostičová, M.
271	Líšková, A., Maďarová, L., Štefkovičová, M., Reizigová, L., Nováková, E., Sabaka, P.
272	Koščálová, A., Brejová, B., Staroňová, E., Mišík, M., Vinař, T., Nosek, J., Čekan, P.
273	Klempa, B., 2021. Surveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia using a
274	novel, multiplexed RT-qPCR assay. Sci Rep. 11(1):20494. doi: 10.1038/s41598-021-
275	99661-7.
276	14. Granato, P.A., Kimball, S.R., Alkins, B.R., Cross, D.C., Unz, M.M., 2021. Comparative
277	evaluation of the Thermo fisher TaqPath [™] COVID-19 combo kit with the Cepheid
278	Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal
279	specimens. BMC Infect Dis. 21(1):623. doi: 10.1186/s12879-021-06347-6.
280	15. Zelyas, N., Pabbaraju, K., Croxen, M.A., Lynch, T., Buss, E., Murphy, S.A., Shokoples
281	S., Wong, A., Kanji, J.N., Tipples, G., 2021. Precision response to the rise of the SARS-
282	CoV-2 B. 1.1. 7 variant of concern by combining novel PCR assays and genome
283	sequencing for rapid variant detection and surveillance. Microbiology spectrum. 9(1)
284	e00315-21. doi: 10.1128/Spectrum.00315-21.
285	16. Vega-Magaña, N., Sánchez-Sánchez, R., Hernández-Bello, J., Venancio-Landeros, A.A.
286	Peña-Rodríguez, M., Vega-Zepeda, R.A., Galindo-Ornelas, B., Díaz-Sánchez, M.
287	García-Chagollán, M., Macedo-Ojeda, G., García-González, O.P., Muñoz-Valle, J.F.
288	2021. RT-qPCR Assays for Rapid Detection of the N501Y, 69-70del, K417N, and
289	E484K SARS-CoV-2 Mutations: A Screening Strategy to Identify Variants with Clinical
290	Impact. Front Cell Infect Microbiol. 11:672562. doi: 10.3389/fcimb.2021.672562.

291	17. Bedotto, M., Fournier, P.E., Houhamdi, L., Levasseur, A., Delerce, J., Pinault, L.,
292	Padane, A., Chamieh, A., Tissot-Dupont, H., Brouqui, P., Sokhna, C., Azar, E., Saile, R.,
293	Mboup, S., Bitam, I., Colson, P., Raoult, D., 2021. Implementation of an in-house real-
294	time reverse transcription-PCR assay for the rapid detection of the SARS-CoV-2
295	Marseille-4 variant. Journal of Clinical Virology. 139: 104814. doi:
296	10.1016/j.jcv.2021.104814.
297	18. Dächert, C., Muenchhoff, M., Graf, A., Autenrieth, H., Bender, S., Mairhofer, H., Wratil,
298	P.R., Thieme, S., Krebs, S., Grzimek-Koschewa, N., Blum, H., Keppler, O.T., 2022.
299	Rapid and sensitive identification of omicron by variant-specific PCR and nanopore
300	sequencing: paradigm for diagnostics of emerging SARS-CoV-2 variants. Med Microbiol
301	Immunol. 211: 71–77. doi: 10.1007/s00430-022-00728-7.
302	
303	

Target Gene	Primer Name	Primer sequence (5'-3')
N	N WT 31-33 Forward	GTAACCAGAATGGAGAACGCA
Ν	N del 31-33 Forward	ACTGGCAGTAACCAGAATGGTG
Ν	N Reverse	CGGTAGTAGCCAATTTGGTCATC
S	Spike WT 143-145 Forward	ATGATCCATTTTTGGGTGTTTATT
S	Spike del 143-145 Forward	GTAATGATCCATTTTTGGACCA
S	Spike Reverse	ACACAAATTCCCTAAGATTTTTGA
S	Spike control Forward	CAACAAAAGTTGGATGGAAAGTG
S	Spike control Reverse	GATCACGCACTAAATTAATAGGC

305	Table 1: List of	primer sets. Deleted nucleotides are in bold.
-----	------------------	---

306

- **Table 2.** Determination of the sensitivity by 7 serials 10-fold dilutions. Diluted samples were
- tested by our SYBR Green- based protocol and by TaqMan RT- qPCR (TaqPath kit).

	CT values (SYB	Ct values (Taq Path kit, S probe)		
Concentration of DNA	Spike del 143-145	N del 31-33	S control	
Dilution Factor 1/10				
50 ng/µl	19.51	19.43	19.07	17.73
5 ng/μl	21.89	21.59	21.42	20.79
0.5 ng/μl	24.99	25	24.65	24.05
0.05 ng/µl	28.58	28.69	28.34	27.89
0.005 ng/ul	30.94	32.1	33.52	31.61
0.0005ng/ul	35.56	35.4	34.32	34.05
0.00005ng/ul	ND	ND	ND	ND

310 ND: Not Detected.

312 Figure Legends

313


Fig 1. The Localization and design of the primers used. The nine nucleotides deleted in S geneand in N gene of Omicron variant are marked in bold.


316


Fig 2. Calibration curves of SYBR Green-based qPCR primers Spike del 143-145, N del 31-33, S control and TaqPath kit. Serially 10-fold diluted cDNA containing the mutations S Δ 143-145 and N Δ 31-33 were amplified and analyzed. a) The threshold cycle (Ct) mean values were plotted against the Log starting quantity (ng/µl). slope, R2 and Eff were determined. Each dilution was assayed in triplicate.

322

Fig 3. The melting curves for the products amplified with the SYBR Green-based qPCR protocol in S-gene target failure samples using the primers: a) Spike del 143-145; b) N del 31-33 and c) Spike control, reveal specific melt peak for each primer set.







<u>Spike WT 143-145</u> FLGVY<u>Y</u>H


21972 ATGATCCATTTTTGG**GTGTTTATT**ACCACAAAAACAACAACAAAGTTGGATGGAAAGTGAGTTCAGAGTTTATT CTAGTGCGAATAATTGCACTTTTGAATATGTCTCTCAGCCTTTTCTTATGGACCTTGAAGGAAAACAGGGTA ATTTCAAAAATCTTAGGGAATTTGTGT 22142

Spike del 143-145

FLDH

┍┻┑┍┻┑┍┻┑

N WT 31-33



28337 <u>GTAACCAGAATGG**AGAACGCAG**</u>TGGGGCCGCGATCAAAACAACGTCGGCCCCAAGGTTTACCCAATAATAC TGCGTCTTGGTTCACCGCTCTCACTCAACATGGCAAGGAAGACCTTAAATTCCCTCGAGGACAAGGCGTT CCAATTAACACCAATAGCAGTCCAGAT<u>GACCAAATTGGCTACTACCG</u> 28523

N del 31-33

┍┺┑┍┺┑┍┻┑

28330 <u>ACTGGCAGTAACCAGAATGGTGG</u>GGGCGCGATCAAAACAACGTCGGCCCCAAGGTTTACCCAATAATACT GCGTCTTGGTTCACCGCTCTCACTCAACATGGCAAGGAAGACCTTAAATTCCCTCGAGGACAAGGCGTT CCAATTAACACCAATAGCAGTCCAGATGACCAAATTGGCTACTACCG 28523